Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04629508
Title To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy.
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ITA | ESP | DEU | BEL | AUT


No variant requirements are available.